Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Idoia Morilla"'
Autor:
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself.
Externí odkaz:
https://doaj.org/article/0111fe9f31fa49208eab155d42059c73
Autor:
Milana Bergamino Sirvén, Adela Fernández-Ortega, Agostina Stradella, Idoia Morilla, Catalina Falo, Silvia Vázquez, Roser Castany, Rafael Villanueva, Sabela Recalde, Valentí Navarro Pérez, Miguel Gil-Gil, Sonia Pernas
Publikováno v:
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-7 (2019)
Abstract Background Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s ef
Externí odkaz:
https://doaj.org/article/4d26cbd7305c4633b2c09988187b9a45
Autor:
Miren Zuazo, Hugo Arasanz, Gonzalo Fernández‐Hinojal, Maria Jesus García‐Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, Maria Jose Lecumberri, Angela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 7, Pp 1-14 (2019)
Abstract The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients w
Externí odkaz:
https://doaj.org/article/3a88dbbc128d40bd80a8b975ab6348a4
Autor:
Luisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, Maite Martínez-Aguillo, Sergio Piñeiro-Hermida, Pablo Ramos, Juan José Lasarte, Ruth Vera, Grazyna Kochan, David Escors
Publikováno v:
Life, Vol 12, Iss 4, p 561 (2022)
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies. Howe
Externí odkaz:
https://doaj.org/article/d7e765f2ef3f4ba0981250f6704e97c3
Autor:
Jorge Gómez-Miragaya, Marta Palafox, Laia Paré, Guillermo Yoldi, Irene Ferrer, Sergi Vila, Patricia Galván, Pasquale Pellegrini, Hector Pérez-Montoyo, Ana Igea, Purificación Muñoz, Manel Esteller, Angel R. Nebreda, Ander Urruticoechea, Idoia Morilla, Sonia Pernas, Fina Climent, María Teresa Soler-Monso, Ana Petit, Violeta Serra, Aleix Prat, Eva González-Suárez
Publikováno v:
Stem Cell Reports, Vol 8, Iss 5, Pp 1392-1407 (2017)
Taxanes are a mainstay of treatment for breast cancer, but resistance often develops followed by metastatic disease and mortality. Aiming to reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PD
Externí odkaz:
https://doaj.org/article/4f17da8dcc6a4c1abea0af3c702c89e0
Autor:
Sonia Pernas, Anna Petit, Fina Climent, Laia Paré, J. Perez-Martin, Luz Ventura, Milana Bergamino, Patricia Galván, Catalina Falo, Idoia Morilla, Adela Fernandez-Ortega, Agostina Stradella, Montse Rey, Amparo Garcia-Tejedor, Miguel Gil-Gil, Aleix Prat
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Externí odkaz:
https://doaj.org/article/ef1c8ba164b94a1e90163cc0ccc47e4e
Autor:
Sonia Pernas, Anna Petit, Fina Climent, Laia Paré, J. Perez-Martin, Luz Ventura, Milana Bergamino, Patricia Galván, Catalina Falo, Idoia Morilla, Adela Fernandez-Ortega, Agostina Stradella, Montse Rey, Amparo Garcia-Tejedor, Miguel Gil-Gil, Aleix Prat
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: HER2-enriched subtype has been associated with higher response to neoadjuvant anti-HER2-based therapy across various clinical trials. However, limited data exist in real-world practice and regarding residual disease. Here, we evaluate t
Externí odkaz:
https://doaj.org/article/2924a0090e4e4cf2b0ccdc985a40dd5b
Autor:
Elisabet Cuyàs, Maria Buxó, Maria José Ferri Iglesias, Sara Verdura, Sonia Pernas, Joan Dorca, Isabel Álvarez, Susana Martínez, Jose Manuel Pérez-Garcia, Norberto Batista-López, César A. Rodríguez-Sánchez, Kepa Amillano, Severina Domínguez, Maria Luque, Idoia Morilla, Agostina Stradella, Gemma Viñas, Javier Cortés, Jorge Joven, Joan Brunet, Eugeni López-Bonet, Margarita Garcia, Samiha Saidani, Xavier Queralt Moles, Begoña Martin-Castillo, Javier A. Menendez
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabete
Externí odkaz:
https://doaj.org/article/d2338fd8195c45919755b3df06f89a20
Autor:
Hugo Arasanz, Miren Zuazo, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Maite Martínez, Idoia Morilla, Gonzalo Fernández, Lucía Teijeira, Pilar Morente, Miriam Echaide, Natalia Castro, Leticia Fernández, Maider Garnica, Pablo Ramos, David Escors, Grazyna Kochan, Ruth Vera
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 7, p 3736 (2021)
Along with the positioning of immunotherapy as a preferential treatment for a wide variety of neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth has been described. This phenomenon has received the name of “hyp
Externí odkaz:
https://doaj.org/article/f4dbbf0526fa43eb9b6e2acfae43b154
Autor:
Gorka Ruiz de Garibay, Francesca Mateo, Agostina Stradella, Rafael Valdés-Mas, Luis Palomero, Jordi Serra-Musach, Diana A. Puente, Ander Díaz-Navarro, Gardenia Vargas-Parra, Eva Tornero, Idoia Morilla, Lourdes Farré, María Martinez-Iniesta, Carmen Herranz, Emmet McCormack, August Vidal, Anna Petit, Teresa Soler, Conxi Lázaro, Xose S. Puente, Alberto Villanueva, Miguel Angel Pujana
Publikováno v:
Disease Models & Mechanisms, Vol 11, Iss 5 (2018)
Understanding the mechanisms of cancer therapeutic resistance is fundamental to improving cancer care. There is clear benefit from chemotherapy in different breast cancer settings; however, knowledge of the mutations and genes that mediate resistance
Externí odkaz:
https://doaj.org/article/0dfb2b95c5954147aa990050eba77efc